SynthesisBMC gastroenterology2025
Population stratified differences between ATG16L1 rs2241880 polymorphism with Crohn's disease risk: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundATG16L1 rs2241880 (T300A), a single-nucleotide variant, plays a controversial role in the development of Crohn's disease (CD).
aimThis meta-analysis aimed to explore the association between rs2241880 and CD among different subgroups by collecting the largest sample size published so far.
methodsWe retrieved articles from China National Knowledge Infrastructure, PubMed, Web of Science, and Embase databases, adhered to the PRISMA 2020 guidelines. The correlation between the rs2241880 variant and CD was assessed with a combined effect size of the calculated 95% confidence interval (CI) and odds ratio (OR). Heterogeneity was assessed by the I
resultsThe rs2241880 G allele is positively correlated with the risk of CD worldwide, with an OR of 1.33 (95% CI: 1.29-1.37) for the comparison of G vs. A. This variant is identified as a risk factor for CD progression across all racial subgroups, particularly highlighting an association between Mongolians and CD risk (G vs. A: OR = 1.24, 95% CI: 1.15-1.34). Furthermore, there are statistically significant differences observed across age subgroups, with adults showing an OR of 1.33 (95% CI: 1.29-1.38) and children an OR of 1.27 (95% CI: 1.10-1.47). Gender-wise, the risk remains significant with a male vs. female comparison yielding an OR of 1.33 (95% CI: 1.29-1.37). Additionally, when comparing the overall co-dominant models, GA carriers exhibited a lower risk compared to GG carriers. Specifically, GA vs. AA showed an OR of 1.30 (95% CI: 1.23-1.38), while GG vs. AA revealed a higher risk with an OR of 1.76 (95% CI: 1.65-1.88).
conclusionThe ATG16L1 rs2241880 G allele is associated with an increased risk of CD globally, acting as a risk factor across various demographics, including age (both adults and children), gender, and particularly within Mongolian populations. A gene dosage-dependent effect may enhance the strength of this association, as GG carriers of the ATG16L1 rs2241880 G/A allele polymorphism exhibit a higher risk for CD compared to GA carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.